- Home
- LSTA
as 07-26-2024 4:00pm EST
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | BASKING RIDGE |
| Market Cap: | 29.0M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 15.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.95 - $3.83 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Lisata Therapeutics Inc. News
LSTA Breaking Stock News: Dive into LSTA Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Medical Device Network
8 days ago
Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial
Exec Edge
8 days ago
Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy
GlobeNewswire
8 days ago
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
Benzinga
9 days ago
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Zacks
10 days ago
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
GlobeNewswire
10 days ago
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
GlobeNewswire
16 days ago
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Compare LSTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LSTA Lisata Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.